That is about as old school as it gets. They are 50,000x less sensitive that molecular assays.
Has ENZ's situation actually deteriorated so much that they are grasping at these straws now?
Antibody assays for Borellia burgdorferi? Really?
Since serology may not be positive until 2 to 4 weeks after onset of ECM, direct detection of Borrelia burgdorferi-specific target DNA sequences using PCR is a promising adjunct to existing diagnostic tests. PCR has shown utility for detection of Borrelia burgdorferi DNA from skin biopsies of ECM lesions, and from synovial and cerebrospinal fluid in late-stage disease.
So, once again, ENZ has partnered with a loser.
Gee, what a big surprise (not).....
They do not make or sell products based on the patents in litigation. And that is what the definition of a patent troll is.
Epigenomics, Polymedco to Team up on North American Launch of Colorectal Cancer Test
October 02, 2013
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Epigenomics said today it has reached a deal with Polymedco to jointly commercialize Epigenomics' Epi proColon colorectal cancer screen in North America.
The test is currently under review by the US Food and Drug Administration, and Germany-based Epigenomics has said that approval is anticipated later this year. Upon approval, Polymedco would deploy its dedicated colorectal cancer sales force, technical support staff, administration, logistics, and other support functions to launch and market the test, Epigenomics said.
Both firms will jointly work on marketing, launch, and development strategies, and collaborate on reimbursement efforts for Epi proColon. Epigenomics will continue to be responsible for manufacturing the test, and for supporting it "from the medical and regulatory point of view, including the activities necessary to achieve inclusion in major cancer screening guidelines" after FDA approval, it said.
As part of the deal, Epigenomics and Polymedco have agreed to a combined transfer price and to share profits, subject to minimum annual sales of test kits to Polymedco.
Based in Cortlandt Manor, NY, Polymedco is the largest provider of colorectal cancer screening tests in North America, according to Epigenomics, and has more than $50 million in annual sales of cancer diagnostic products. Its customer base includes more than 1,500 laboratories.
"Polymedco's commitment to the [colorectal cancer] screening space will accelerate our commercial rollout in North America and will mean a significant time and resource advantage for Epigenomics in the launch of Epi proColon," Noel Doheny, CEO of Epigenomics' US subsidiary, said in a statement.
What else should you expect from a PR from them that only admits that they have sunk so low that they have simply become trans-shippers of blood specimens to another company's lab for testing?
Like I said yesterday, ENZ didn't announce THEY were performing the test. The PR only admits that they have sunk so low that they have simply become trans-shippers of blood specimens to another company's lab for testing.
Actually, Enzo has a SINGLE lab and a number of PSC (patient service centers). All patient service centers are are places to get blood drawn and samples collected.
You should have actually done a search for CLIA, NYDOH and other certification numbers and you would have known they only have a single lab.